Abstract Library

#3067 Somatostatin Analogs in Real‐World Practice for Patients with Metastatic Neuroendocrine Tumors: A Single Institution Experience in the Ouest of Algeria (CHU Oran)

Introduction: The efficacy of somatostatin analogs (SSAs) were clearly established trough pivotal trials as first‐line agents for neuroendocrine tumors (NETs), but their use in clinical practice is largely unknown.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Ameziane N, Behourah Z, Aida M, Ahed Messaoud M, Bousahba A,

Keywords: GEP-NET, Somatostatin analogs, anti proliferative action, anti secretory action, Management real world practice,

#2969 Lanreotide Autogel and Octreotide LAR Treatment Patterns: Results from a Nationwide French Retrospective Study

Introduction: Lanreotide autogel (LAN) and octreotide LAR (OCT) are long acting somatostatin analogues (LA-SSAs) used to treat acromegaly and gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Previous studies conducted in North America and Sweden showed some differences between both LA-SSAs in terms of dose and persistence.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Fagnani F, Feuilly M, Marteau F, de Zélicourt M, Kamenicky P,

Keywords: somatostatin analogues, treatment patterns, resource use,

#2829 Everolimus-Induced Pneumonitis in Patients with Neuroendocrine Neoplasms: Multinational Study on Risk Factors and Outcomes

Introduction: The incidence and risk factors for everolimus-induced pneumonitis (EiP) have been poorly studied in patients (pts) with neuroendocrine neoplasms (NEN) outside of clinical trials.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Taboada R

Authors: Taboada R, Riechelmann R, Mauro C, Barros M, Hubner R,

Keywords: neuroendocrine, everolimus, pneumonitis,

#2160 A Comparison of Retrospective Database Analysis with Chart Review in Patients Receiving Somatostatin Analog (SSA) in Neuroendocrine Tumors (NETs)

Introduction: SSAs are recommended for the treatment of locoregional/metastatic NET.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Klink A, Feinberg B, Yu H, Ray D, Pulgar S,

Keywords: neuroendocrine tumors, somatostatin analogues, lanreotide, octreotide, carcinoid syndrome,

#2106 Long-Acting Somatostatin Analogue (LA-SSA) Treatment Patterns in Patients Diagnosed with Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Grade 1 or 2 (G1/G2) in Sweden

Introduction: The main pharmacological treatment for metastatic GEP-NET G1/G2 is LA-SSA.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Berthon A

Authors: Berthon A, Björstad �, Granfeldt D, Marlow T, Dinét J,

Keywords: metastatic, GEP-NET, somatostatin analogues, treatment,